98%
921
2 minutes
20
Background: Postoperative urinary retention (POUR), a common complication after spine surgery, can contribute to longer hospital stays, urinary tract infection, pain, and morbidity. This study aimed to determine the incidence of POUR in patients who underwent lumbar decompression and to construct a predictive model for preoperatively identifying high-risk patients.
Methods: This was a retrospective review of patients undergoing primary lumbar decompression from 2017 to 2023. Demographic characteristics, comorbidities, and perioperative data were collected. Factors associated with POUR were assessed, and multivariable logistic regressions were performed to identify independent predictors of the development of POUR. A nomogram to predict the development of POUR was developed within a training subset, based on a multivariable logistic regression model of preoperative variables, followed by the internal validation of the model in a validation subset and assessment of its performance.
Results: Of the 1,938 patients included in this study, 133 (6.9%) developed POUR. Following multivariable analysis, the following risk factors for POUR were identified: a history of urinary retention (odds ratio [OR], 4.956 [95% confidence interval (CI), 2.157 to 11.383]; p < 0.001), insurance that was not commercial (private) (OR, 2.256 [95% CI, 1.298 to 3.922]; p = 0.004), intraoperative Foley catheter use (OR, 5.967 [95% CI, 3.506 to 10.156]; p < 0.001), inpatient opioid consumption of >93 morphine milligram equivalents (OR, 1.898 [95% CI, 1.220 to 2.952]; p = 0.004), and anticholinergic medication use during hospitalization (OR, 3.450 [95% CI, 2.313 to 5.148]; p < 0.001). The nomogram, which included the preoperative variables of male sex, age of >65 years, history of urinary retention, history of benign prostatic hyperplasia, not having commercial insurance, and American Society of Anesthesiologists (ASA) classification of >2, demonstrated good discrimination in the training subset (area under the curve [AUC], 0.725 [95% CI, 0.673 to 0.776]) and the validation subset (AUC, 0.709 [95% CI, 0.599 to 0.819]). The Hosmer-Lemeshow goodness-of-fit test demonstrated that the model fit the data well (chi-square test = 9.063; p = 0.170).
Conclusions: The incidence of POUR after lumbar decompression surgery was found to be 6.9%. A history of urinary retention, not having commercial (private) insurance, intraoperative Foley catheter usage, inpatient opioid consumption of >93 morphine milligram equivalents, and the administration of anticholinergic medication during hospitalization increased the risk of developing POUR. Furthermore, we constructed a preoperative predictive model with good performance metrics to help clinicians to identify patients at elevated risk for developing POUR.
Level Of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2106/JBJS.24.01030 | DOI Listing |
Br J Nurs
September 2025
Senior Bladder, Bowel and Stoma Care, Clinical Nurse Specialist and Nurse Prescriber, Hollister Ltd.
The aim of this case study is to illustrate the benefits of clean intermittent self-catheterisation (CISC) in individuals with multiple sclerosis (MS) who have incomplete bladder emptying. People with MS usually start to experience bladder symptoms 6-8 years after diagnosis, although some individuals experience symptoms from the time of diagnosis. MS is a condition of the central nervous system that affects the brain and spinal cord; the immune system attacks myelin, a substance that protects the nerve fibres, preventing messages travelling smoothly along the fibres to control the whole body, which includes the nerves that control the bladder.
View Article and Find Full Text PDFBMJ Open
September 2025
Department of Nursing, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
Objectives: This scoping review aimed to synthesise the currently available evidence and influencing factors on the occurrence of postoperative urinary retention (POUR) in older patients with hip fractures.
Design: This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guideline.
Data Sources: PubMed, Cochrane Library, CINAHL, Web of Science, Chinese National Knowledge Infrastructure, Wanfang Data and Sinomed databases were systematically searched from database inception to 1 September 2024.
ACS Appl Mater Interfaces
September 2025
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Benign prostatic hyperplasia (BPH) presents a significant clinical challenge, with conventional therapies carrying substantial risks, including urinary retention, sexual dysfunction, and prolonged recovery. To address the urgent need for safer, ultra-minimally invasive alternatives, we developed a sonosensitizing nanoplatform using copper-manganese-doped mesoporous silica nanoparticles (Cu-Mn@SiO) for ultrasound-induced sonodynamic therapy (SDT). Here, we demonstrate that this innovative strategy provides highly effective and precisely targeted therapy for BPH.
View Article and Find Full Text PDFJ Clin Nurs
September 2025
Nursing and Midwifery Services, Northern Sydney Local Health District, St Leonards, New South Wales, Australia.
Aims: To describe diagnostic categories and comorbidities associated with increased risk of readmission within 28 days among older adults.
Methods: Retrospective observational study of all hospital admissions following ED attendance by patients aged ≥ 60 years between July 2020 and June 2023. Index and subsequent 28-day readmission were identified using ED data and hospital discharge records.
Pharmacotherapy
September 2025
Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina, USA.
Lecanemab is an amyloid-targeted antibody indicated for treating patients with amyloid-confirmed early Alzheimer's Disease in mild dementia or mild cognitive impairment stages. We report here a case of a subject with early stage of Alzheimer's Disease dementia, amyloid positive, who developed severe acute urinary retention following his first dose of intravenous lecanemab. His urinary retention resolved after a week but recurred following the second intravenous dose 2 weeks later.
View Article and Find Full Text PDF